TARS Rentabilitas dodolan reged Tarsus Pharma

Simbol resmi perusahaan Tarsus Pharma (TARS)

Revenue volatility from XDEMVY sales impacts the gross profit margin level, for which the current chart on GURU.Markets lists 93.20 as the latest metric reading. Ambitious personnel motivated by stock options ensure stability. Furthermore, expansion into ophthalmology makes the growth of Tarsus Pharmaceuticals (TARS) independent of economic cycles, smoothing market fluctuations through the scaling of therapy.

TARS Tingkat bathi miturut bathi reged Tarsus Corp (04.07.2022 - 20.11.2026)

Rincian analitis lan laporan data perusahaan Tarsus Pharmaceuticals (TARS)

- nilai saham lan prakiraan konsensus rega:
Analisis dhasar perusahaan:TARS - Tarsus Pharma
Produk asil prodhuksi Tarsus Corp

Professional capital evaluates Tarsus Pharmaceuticals (TARS) through the monetization efficiency of Xdemvy and the potential for pipeline expansion, analyzing the business's ability to generate excess cash flow. By examining the gross profit margin, the investor determines the portion of revenue remaining after direct production costs, which allows for an assessment of operational returns and prevents overpaying for the asset amidst market competition.